AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse

According to CNBC US Top News, shares of AstraZeneca fell nine percent after one of the U.K. drugmaker's heart-drug trials missed its mark, a rare stumble for the pharmaceutical heavyweight.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton